HDL cholesterol: reappraisal of its clinical relevance

Clinical Research in Cardiology, Journal Year: 2017, Volume and Issue: 106(9), P. 663 - 675

Published: March 24, 2017

While several lines of evidence prove that elevated concentrations low-density lipoproteins (LDL) causally contribute to the development atherosclerosis and its clinical consequences, high-density are still widely believed exert atheroprotective effects. Hence, HDL cholesterol (HDL-C) is in general considered as "good cholesterol". Recent research, however, suggests this might not always be case a fundamental reassessment significance HDL-C warranted. This review article based on selective literature review. In individuals without history cardiovascular events, low inversely associated with risk future events. relationship may, apply patients metabolic disorders or manifest disease. The classical function mobilise from extrahepatic tissues for delivery liver excretion. These roles metabolism well many other biological functions particles dependent number protein lipid composition particles. They poorly reflected by concentration. can even negative vascular effects, if pathologically altered. High serum therefore no longer regarded protective. line this, recent pharmacological approaches raise concentration have been able show reductions outcomes. contrast LDL (LDL-C), correlates only healthy individuals. calculation ratio LDL-C useful all patients. Low should prompt examination additional inflammatory pathologies. An increase through lifestyle change (smoking cessation, physical exercise) has positive effects recommended. However, currently valid target drug therapy.

Language: Английский

---

Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation

Nature Immunology, Journal Year: 2019, Volume and Issue: 21(1), P. 30 - 41

Published: Dec. 9, 2019

Language: Английский

---

Lipid management in patients with chronic kidney disease

Nature Reviews Nephrology, Journal Year: 2018, Volume and Issue: 14(12), P. 727 - 749

Published: Oct. 25, 2018

Language: Английский

---

High Density Lipoprotein Cholesterol and the Risk of All-Cause Mortality among U.S. Veterans

Clinical Journal of the American Society of Nephrology, Journal Year: 2016, Volume and Issue: 11(10), P. 1784 - 1793

Published: Aug. 11, 2016

Background and objectives The relationship between HDL cholesterol all-cause mortality in patients with kidney disease is not clear. We sought to characterize the of risk death examine association by eGFR levels. Design, setting, participants, & measurements built a cohort 1,764,986 men who were United States veterans at least one October 2003 September 2004 followed them until 2013 or death. Results Patients low had higher burden comorbid illnesses. Over median 9.1 years (interquartile range, 7.7–9.4 years), 26,247 (40.1%), 109,222 (32.3%), 152,625 (29.2%), 113,785 (28.5%), 139,803 (31.8%) participants ≤25, >25 <34, ≥34 ≤42, >42 <50, ≥50 mg/dl died. In adjusted survival models, compared referent group (≤25 mg/dl), intermediate levels (>25 <50 mg/dl) associated lower across all eGFR. was partially abrogated those high (≥50 similar category among eGFR<30 ≥90 ml/min per 1.73 m 2 . Analysis deciles spline analyses suggest that follows U-shaped curve. There significant interaction attenuated salutary ( P for <0.01). Presence coronary artery eGFR≥60 <0.05). Conclusions Our results show categories. modified cardiovascular disease.

Language: Английский

---

Novel methodologies for biomarker discovery in atherosclerosis

European Heart Journal, Journal Year: 2015, Volume and Issue: 36(39), P. 2635 - 2642

Published: June 5, 2015

Identification of subjects at increased risk for cardiovascular events plays a central role in the worldwide efforts to improve prevention, prediction, diagnosis, and prognosis disease decrease related costs. Despite their high predictive value on population level, traditional factors fail fully predict individual risk. This position paper provides summary current vascular biomarkers other than with special focus emerging −omics technologies. The definition identification use classical are introduced, we discuss limitations such as sensitivity C-reactive protein (hsCRP) or N-terminal pro-brain natriuretic peptide (NT-proBNP). is complemented by circulating plasma biomarkers, including high-density lipoprotein (HDL), conceptual shift from HDL cholesterol levels composition/function assessment. Novel sources plasma-derived markers include microparticles, microvesicles, exosomes omics-based analytics. Measurement micro-RNAs, short RNA sequences regulating gene expression, has attracted major interest search novel biomarkers. Also, mass spectrometry nuclear magnetic resonance spectroscopy have become key complementary technologies new proteomic searches quantification small metabolites lipids (metabolomics lipidomics). In particular, pro-inflammatory lipid gained much field. Our consensus statement concludes leads needs biomarker research near future prediction.

Language: Английский

---

Arterial Stiffness in the Heart Disease of CKD

Journal of the American Society of Nephrology, Journal Year: 2019, Volume and Issue: 30(6), P. 918 - 928

Published: April 30, 2019

CKD frequently leads to chronic cardiac dysfunction. This complex relationship has been termed as cardiorenal syndrome type 4 or cardio-renal link. Despite numerous studies and reviews focused on the pathophysiology therapy of this syndrome, role arterial stiffness overlooked. In regard, several pathogenic factors, including uremic toxins ( i.e. , uric acid, phosphates, endothelin-1, advanced glycation end-products, asymmetric dimethylarginine), can be involved. Their effect wall, direct mediated by inflammation oxidative stress, results in stiffening decreased vascular compliance. The increase aortic increased workload reduced coronary artery perfusion pressure that, turn, may lead microvascular ischemia. Conversely, associated with survival. Several approaches considered reduce improve function patients CKD. review primarily discusses current understanding mechanisms concerning toxins, stiffening, impaired function, therapeutic options

Language: Английский

---

Targeting innate immunity-driven inflammation in CKD and cardiovascular disease

Nature Reviews Nephrology, Journal Year: 2022, Volume and Issue: 18(12), P. 762 - 778

Published: Sept. 5, 2022

Language: Английский

---

Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations

Nature Reviews Nephrology, Journal Year: 2021, Volume and Issue: 17(8), P. 528 - 542

Published: May 10, 2021

Language: Английский

---

Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk

European Heart Journal, Journal Year: 2015, Volume and Issue: unknown, P. ehv352 - ehv352

Published: Aug. 6, 2015

High-density lipoproteins (HDLs) are considered as anti-atherogenic. Recent experimental findings suggest that their biological properties can be modified in certain clinical conditions by accumulation of serum amyloid A (SAA). The effect SAA on the association between HDL-cholesterol (HDL-C) and cardiovascular outcome remains unknown.We examined HDL-C with mortality Ludwigshafen Risk Cardiovascular Health (LURIC) study, which included 3310 patients undergoing coronary angiography. To validate our findings, we analysed 1255 participants German Diabetes Dialysis study (4D) 4027 Cooperative Research Region Augsburg (KORA) S4 study. In LURIC, concentrations predicted all-cause mortality. low SAA, higher was associated lower contrast, high increased mortality, indicating indeed modifies beneficial HDL. We complemented these observations vitro experiments, impaired vascular functions further derived a formula for simple calculation amount biologically 'effective' based measured from LURIC 4D KORA studies, found not outcomes, whereas calculated significantly better outcome.The acute-phase protein effects several conditions. concomitant measurement is simple, useful, clinically applicable surrogate functionality

Language: Английский

---

Disorders of Lipid Metabolism in Chronic Kidney Disease

Blood Purification, Journal Year: 2018, Volume and Issue: 46(2), P. 144 - 152

Published: Jan. 1, 2018

Cardiovascular disease (CVD) is the leading cause of death in chronic kidney (CKD). One most important pathophysiological mechanisms for CVD patients with CKD widespread and possibly accelerated formation atherosclerotic plaques due to hyperlipidemia, uremic toxins, inflammation, oxidative stress, endothelial dysfunction. Recent studies showed that level oxidized low-density lipoprotein cholesterol increases, high--density dysfunction occurs as function declines inflammation becomes more prevalent. In this review, we aimed discuss effect dysfunction, on lipid -profile.

Language: Английский

---